logo-loader
RNS
Vulcan Two Group plc

Grant of Options and Director Dealing

RNS Number : 9350Z
Molecule Group PLC
21 October 2026
 

Molecule Group plc

(the "Company", "Group" or "Molecule")

 

Grant of Options and Director Dealing

 

Molecule Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, announces that on 21 October 2026 the Company granted Susan Clement Davies, the Company's Chair and Non-Executive Director, 47,619 options ("Options") over ordinary shares of 10 pence each in the Company ("Ordinary Shares"). The Options will vest over 5 years, with 40% vesting on the second anniversary of grant and the remaining 60% vesting in equal instalments on the third, fourth and fifth anniversaries of grant. The Options are exercisable at a price of £2.10 per Ordinary Share.

 

The Notification of Dealing is set out below. This notification is issued in accordance with Article 19.3 of the UK Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Susan Clement Davies

2

Reason for the notification

a)

Position/Status:

 

Chair and Non-Executive Director

b)

Initial Notification/Amendment:

 

Initial Notification

3

Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor

a)

Name:

Molecule Group plc

b)

LEI:

213800W5TPGBRC2V7L20

4.

Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.

a)

Description of the financial instrument:

 

Ordinary Shares of 10 pence each

 

b)

Identification code:

ISIN: GB00BTQLZH16

 

b)

Nature of the transaction:

 

Award of options over Ordinary Shares

c)

Price(s) and volume(s):

 

Price

Volume

Nil

47,619

 

d)

Aggregated volume:

Price:

Single Transaction

e)

Date of the Transaction:

21-10-2026

f)

Place of the Transaction:

Outside a trading venue

 

 

For further information please contact:

 

Molecule Group plc

Michael Kraftman, Chief Executive Officer

Keith Butcher, Chief Financial Officer

Brendan O'Brien, Chief Operating Officer

investors.molecule.co.uk

Email: corporate@molecule.co.uk

Canaccord Genuity Limited
(Nominated Adviser and Sole Broker)

Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott

Tel: +44 (0) 20 7523 8000
 

Alma Strategic Communications
(Financial PR)

Justine James / Sam Modlin / Will Merison

Email: molecule@almastrategic.com

Tel: +44 (0) 20 3405 0205

 

Notes to Editors

Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZMZGKMRGVZM
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read